Health & Fitness
Health and Fitness
Health and Fitness
Mon, May 24, 2010
Fri, May 21, 2010 Positron Sees Tenfold Increase in Attriusa" Quote Proposals
INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:[ POSC ]) (the aCompanya) a molecular imaging solutions company focused on Nuclear Cardiology, states that over the first 4 months of 2010 that it has seen tremendous interest in its Attriusa" dedicated cardiac PET scanner. The Attriusa" was introduced in the 4th quarter of 2009 and has been met with critical acclaim throughout the molecular imaging industry.
Patrick G. Rooney, Positron Corporationa™s CEO states, aThe Nuclear Cardiology industry is experiencing a shift from SPECT to PET as a result of molly shortages combined with changes in reimbursement. Positron is in an ideal position to capitalize on this shift more so than any other imaging company. The Attriusa" is a state of the art, Frost & Sullivan New Product Innovation Award winning, device that was designed to be optimized for Cardiac imaging allowing physicians an easy transition to PET. Our pipeline for PET systems has had significant increases each month since we launched the Attriusa" late last year. Our current pipeline has over 55 potential and/or pending sales with the second half on the year still too follow. We have done a very good job of positioning Positron to meet this new demand. Based on the current interest we believe we will meet or exceed our projected system sales moving forward. Positrona™s objective is to be the leader in cardiac PET solutions. We believe we will continue to see substantial growth from both devices and radiopharmaceuticals."
About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attriusa", a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at [ www.positron.com ].
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information, please contact Positron Corporation at (317) 576-0183.
